Johnson and Johnson (JNJ)

[Chrism0000]

Will J&J buy them down the road? HENDERSON, Nev.--(BUSINESS WIRE)--United Health Products, Inc. (OTC: UEEC) (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp, a patented Oxidized Regenerated Cellulose (ORC), today announced that the Journal of Wound Care, headquartered in London, England, has informed the Company that UHP’s submitted article, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, has been accepted for publication in the November 2020 edition. This article, which was peer reviewed, was authored by Raymond Schaerf, MD, Sasan Najibi, MD, John Conrad, MD, and Gerard Abate, MD. This journal submission highlights the results of the study showing HemoStyp’s superiority to Surgicel®, an Ethicon Inc. product, a division of Johnson & Johnson.

Dr. Gerard Abate, Chief Medical Officer, United Health Products, stated: “This is the first head-to-head trial of two ORCs. The data demonstrates that HemoStyp consistently achieved hemostasis faster than Surgicel in all surgical classes studied in less than two minutes, whereas Surgicel could not and failed to control bleeding in six (6) patients where the control timed out at 10 minutes. Based on the overall data, upon anticipated PMA approval for class III FDA surgical use, surgeons will have a superior product to utilize for low grade surgical bleeds.”